X-100296269-A-G
Position:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_001184880.2(PCDH19):c.*8T>C variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000566 in 1,180,965 control chromosomes in the GnomAD database, including 3 homozygotes. There are 174 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.0028 ( 0 hom., 89 hem., cov: 23)
Exomes 𝑓: 0.00033 ( 3 hom. 85 hem. )
Consequence
PCDH19
NM_001184880.2 3_prime_UTR
NM_001184880.2 3_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.0850
Genes affected
PCDH19 (HGNC:14270): (protocadherin 19) The protein encoded by this gene is a member of the delta-2 protocadherin subclass of the cadherin superfamily. The encoded protein is thought to be a calcium-dependent cell-adhesion protein that is primarily expressed in the brain. Mutations in this gene on human chromosome X are associated with sporadic infantile epileptic encephalopathy and to a female-restricted form of epilepsy (EFMR; also known as PCDH19RE). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BP6
Variant X-100296269-A-G is Benign according to our data. Variant chrX-100296269-A-G is described in ClinVar as [Benign]. Clinvar id is 138595.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-100296269-A-G is described in Lovd as [Benign].
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00283 (317/112102) while in subpopulation AFR AF= 0.0095 (293/30854). AF 95% confidence interval is 0.0086. There are 0 homozygotes in gnomad4. There are 89 alleles in male gnomad4 subpopulation. Median coverage is 23. This position pass quality control queck.
BS2
High Hemizygotes in GnomAd4 at 89 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PCDH19 | NM_001184880.2 | c.*8T>C | 3_prime_UTR_variant | 6/6 | ENST00000373034.8 | NP_001171809.1 | ||
PCDH19 | NM_001105243.2 | c.*8T>C | 3_prime_UTR_variant | 5/5 | NP_001098713.1 | |||
PCDH19 | NM_020766.3 | c.*8T>C | 3_prime_UTR_variant | 5/5 | NP_065817.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PCDH19 | ENST00000373034 | c.*8T>C | 3_prime_UTR_variant | 6/6 | 1 | NM_001184880.2 | ENSP00000362125.4 |
Frequencies
GnomAD3 genomes AF: 0.00283 AC: 317AN: 112050Hom.: 0 Cov.: 23 AF XY: 0.00260 AC XY: 89AN XY: 34218
GnomAD3 genomes
AF:
AC:
317
AN:
112050
Hom.:
Cov.:
23
AF XY:
AC XY:
89
AN XY:
34218
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000876 AC: 159AN: 181466Hom.: 1 AF XY: 0.000638 AC XY: 43AN XY: 67420
GnomAD3 exomes
AF:
AC:
159
AN:
181466
Hom.:
AF XY:
AC XY:
43
AN XY:
67420
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000329 AC: 352AN: 1068863Hom.: 3 Cov.: 26 AF XY: 0.000251 AC XY: 85AN XY: 338411
GnomAD4 exome
AF:
AC:
352
AN:
1068863
Hom.:
Cov.:
26
AF XY:
AC XY:
85
AN XY:
338411
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00283 AC: 317AN: 112102Hom.: 0 Cov.: 23 AF XY: 0.00260 AC XY: 89AN XY: 34280
GnomAD4 genome
AF:
AC:
317
AN:
112102
Hom.:
Cov.:
23
AF XY:
AC XY:
89
AN XY:
34280
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | May 22, 2014 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 16, 2013 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at